MyProstateScore

Lorem ipsum dolor sit amet, pri putant definitionem eu, an unum numquam sapientem vis, per ad eripuit adipisci. Modo labitur voluptaria his an. Te has clita menandri, tibique patrioque eos at. Constituam disputando eam cu, putant eligendi id mea.

MPS PERFORMANCE

98%

Negative
predictive value

98%

Sensitivity

27%

Biopsies
prevented

1,700

# of samples in
performance
studies

Lorem ipsum dolor sit amet, pri putant definitionem eu, an unum numquam sapientem vis, per ad eripuit adipisci. Modo labitur voluptaria his an. Te has clita menandri, tibique patrioque eos at. Constituam disputando eam cu, putant eligendi id mea.

TITLE

Lorem ipsum dolor sit amet, pri putant definitionem eu, an unum numquam sapientem vis, per ad eripuit adipisci. Modo labitur voluptaria his an. Te has clita menandri, tibique patrioque eos at. Constituam disputando eam cu, putant eligendi id mea.

Lorem ipsum dolor sit amet, pri putant definitionem eu, an unum numquam sapientem vis, per ad eripuit.

PUBLICATIONS

Wei et al. J Clin Oncol. 2014;32:4066-4072

Urinary PCA3 test improves detection of prostate cancer

- 859 patients prospectively enrolled at 11 centers as part of a National Cancer Institute validation study

- Urinary samples were collected for PCA3 measurement prior to prostate biopsy

- Addition of PCA3 score to risk assessment with clinical variables (i.e. PCPT risk calculator) significantly improved detection of cancer and high-grade cancer

- This finding was true for patients undergoing t heir first biopsy (AUC for high-grade cancer; 0.78) and for patients who had previosly undergone a negative biopsy (AUC for high-grade cancer; 0.79)

Leyten et al. Eur Urol. 2014;65:534-542.

Urinary T2:ERG measurement improves detection of prostate cancer and high-grade cancer

-443 men prospectively enrolled at six centers

 

-Urinary samples were collected for PCA3 and T2:ERG measurement prior to prostate biopsy

 

-Addition of urinary PCA3 and T2:ERG measures to a clinical risk calculator each significantly improved prediction of prostate cancer (AUC: 0.83 for PCA3, 0.84 for T2:ERG)

 

-Addition of urinary T2:ERG measures further improved detection of high-grade cancer (AUC: 0.84)

 

-Combined use of urinary PCA3 and T2:ERG would have allowed 35% of patients to avoid prostate biopsy

Sanda et al. JAMA Oncol. 2017;3:1085-1093.

Combined use of urinary PCA3 and T2:ERG testing is sensitive for aggressive cancer, avoids unnecessary biopsies, and provides healthcare cost savings

-1077 patients underwent urinary PCA3 and T2:ERG testing prior to initial prostate biopsy.

 

-In the validation cohort (n=561), addition of PCA3 and T2:ERG scores nearly doubled testing specificity for high-grade cancer, from 17% with PSA alone to 33% with PSA, PCA3, and T2:ERG. 

 

-Sensitivity of the combined testing approach was 93% for high-grade cancer, and the AUC was 0.81.

 

-Use of combined PCA3 and T2:ERG testing would have avoided 42% of unnecessary prostate biopsies (those that are negative or detect low-grade cancer); diagnosis would have been delayed in only 7% of high-grade cancers. 

 

-Compared to biopsying all men with abnormal PSA, use of urinary PCA3 and T2:ERG was estimated to save between $1200 and $2100 per patient.

Tomlins et al. Eur Urol. 2016;70:45–53.

Combining urinary PCA3 and T2:ERG with serum PSA provides highly accurate prediction of high-grade cancer: the MyProstateScore test

-Adding urinary PCA3 and T2:ERG scores to serum PSA, the MyProstateScore test was developed for detection of high-grade cancer in 711 patients.

 

-MPS improved high-grade cancer detection relative to serum PSA alone (AUC: 0.77 vs. 0.65) and when combined with clinical risk factors (AUC 0.78 vs. 0.71).

 

-MPS improved high-grade cancer detection in all populations with sufficient data (>50 patients) for testing: initial biopsy, repeat biopsy, normal rectal examination, suspicious rectal examination, and various PSA levels (< 3, 3-10, >10 ng/ml). 

 

-Use of MPS would have avoided prostate biopsy in nearly a quarter of patients, while delaying detection of only 2.7% of high-grade cancers.

WHITE LOGO.PNG
INFORMATION
CONTACT